Cardiac fibrosis is a major health concern that affects millions of people worldwide and has a significant impact on the progression of many heart diseases. Despite its prevalence, there is currently no preventive or curative treatment for this condition due to the elusive mechanism of fibrosis and the lack of specific targets. However, recent developments in imaging technology and therapeutic agents offer new hope in the fight against cardiac fibrosis. In their recent paper Groen et al. explored how a novel 3D cryo correlative light and X-ray tomography (CLXT) imaging approach could be used to investigate a promising antifibrotic treatment for myocardial fibrosis, using a Linkam CMS196 to pre-screen vitrified grids. By incorporating this stage into their workflow, the researchers were able to remove damaged grids and locate cells of interest, ultimately saving valuable beamline time and increasing their efficiency.